Emergent BioSolutions (EBS) Divestments (2023)
Emergent BioSolutions' (EBS) quarterly Divestments came in at $74.9 million in Q2 2023.
Emergent BioSolutions (EBS) Divestments (2023) Analysis & Trends
Emergent BioSolutions' Divestments history runs 1 years deep, the most recent figure standing at $74.9 million for Q2 2023.
- On a quarterly basis, Divestments changed N/A year-over-year to $74.9 million in Q2 2023; TTM through Dec 2024 was $74.9 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $110.2 million, down 59.22% from the prior year.
- Divestments steadied at $74.9 million in Q2 2023 per EBS's latest filing.
- Across five years, Divestments topped out at $74.9 million in Q2 2023 and bottomed at $74.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 42.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.28 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 63.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 74.90 Mn |